Gelteq Limited (GELS)
| Market Cap | 11.14M -34.1% |
| Revenue (ttm) | 270,853 +188.3% |
| Net Income | -4.36M |
| EPS | -0.47 |
| Shares Out | 10.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 387,234 |
| Open | 1.060 |
| Previous Close | 1.140 |
| Day's Range | 0.960 - 1.090 |
| 52-Week Range | 0.387 - 2.020 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 29, 2026 |
About GELS
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Financial Performance
In fiscal year 2025, Gelteq's revenue was 413,132, an increase of 188.27% compared to the previous year's 143,313. Losses were -6.65 million, 87.4% more than in 2024.
Financial numbers in AUD Financial StatementsNews
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for phar...
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collabor...
Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center...
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® tec...
Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market LAS VEGAS, NV / ACCESS Newswire / May 14, 2026 / Health...
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercializat...
Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million
2025 Non-GAAP Net Income Totaled $162,000 or $0.02 Per Share Record Results Driven by Fifth Sequential Quarter of Record-Setting Revenues, with the Momentum Setting Stage for Another Year of Double-Di...
Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million
Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026 LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts I...
Gelteq, Healthy Extracts enter MOU for manufacturing, commercial partnership
Gelteq (GELS) and Healthy Extracts announced the signing of a Memorandum of Understanding formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based...
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) and Healthy Extracts™ Inc. (“Healthy Extracts”) today announced the signing of a Memorandum of Understan...
Gelteq announces preclinical results on medicinal cannabinoid absorption
Gelteq (GELS) announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings d...
Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced ...
Gelteq announces new partnership with Hong Kong Flag Football Program
Gelteq (GELS) announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq’s advanced hydration and sports performance formulations into the training and...
Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
Collaboration Combines Growing International Interest in Gelteq's Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles Collaboration ...
Gelteq entered into three year sales agreement with Mana Health
Gelteq (GELS) announced that it has entered into a three year sales agreement with Shenzhen Mana Health Management under which Mana will distribute consumer nutritional products within China using Gel...
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq's Nutritional Product Expansion into China
Agreement includes minimum annual order commitments totalling approximately USD $1.3 million Agreement includes minimum annual order commitments totalling approximately USD $1.3 million
Gelteq announces preclinical findings from study of gel-based platform
Gelteq (GELS) announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical d...
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced ...
Gelteq to Present at Investor Summit Virtual on December 9, 2025
MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit...
Gelteq announces ‘positive’ preclinical results for its gel formulation
The company states: “Gelteq (GELS) Limited announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market referen...
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes
Gelteq Annual report: Q4 2025
Gelteq has published its Q4 2025 annual report on November 17, 2025.
Healthy Extracts Reports Record Q3 2025, with Revenue up 23%
LAS VEGAS, NV / ACCESS Newswire / November 14, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in plant-based nutraceutical innovations, reported results for the third quarter and nine months ende...
Nutraceutical Technology Leader, Healthy Extracts, Invited to Present at the Trickle Research Microcap Conference on November 13, 2025
LAS VEGAS, NV / ACCESS Newswire / November 11, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in science-based nutraceuticals and oral delivery technology for transformational health and longevit...
Gelteq announces commencement of preclinical trial for poorly soluble drugs
Gelteq (GELS) announced it has started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble drugs. Gelteq will conduct the study with Monash Univers...